Indegene IPO Receives Strong Response, Fully Subscribed on Day 1 | Institutional Investors Show Confidence, Retail Demand High | The initial public offering (IPO) of Indegene Limited witnessed a robust response from investors as it was fully subscribed on the first day of bidding. The strong demand underscores investor confidence in the healthcare technology firm’s growth prospects.
Subscription Details
The IPO, which opened for subscription today, garnered significant interest from both institutional and retail investors. The public issue received bids for 1.67 times the offered shares by the end of the first day. Notably, the portion reserved for non-institutional investors (NIIs) was oversubscribed by 3.7 times, indicating strong demand from high net-worth individuals and other non-institutional entities.
Institutional Confidence
Institutional investors also showed a vote of confidence in Indegene, with the company raising ₹548.77 crore from anchor investors ahead of the IPO. This strong anchor book reflects the trust of institutional investors in Indegene’s business model and growth potential.
Retail Investor Participation
Retail investors, too, demonstrated keen interest in the IPO, with the retail portion being oversubscribed on the first day itself. This highlights retail investors’ appetite for quality offerings in the primary market.
About Indegene
Indegene is a Mumbai-based company that specializes in providing digital and technological solutions to the healthcare industry. The company aims to leverage its expertise in digital innovation to transform healthcare delivery and improve patient outcomes. With a focus on data analytics, artificial intelligence, and other emerging technologies, Indegene has positioned itself as a leader in the healthcare tech space.
Offering Details
The IPO of Indegene comprises fresh issue of shares worth ₹1,842 crore. The price band for the IPO has been set at ₹430-452 per share. The proceeds from the IPO will be utilized by the company for various purposes including acquisitions and general corporate purposes.
Analyst Views
Analysts have been positive about Indegene’s IPO, citing its strong business fundamentals and growth prospects in the healthcare technology sector. The company’s innovative solutions and strong client base have been key drivers of investor interest.
Outlook
With the IPO fully subscribed on the first day itself, Indegene’s listing is anticipated to be one of the significant events in the market. The strong response reflects investor confidence in the company’s business model and growth trajectory. As the bidding continues, market watchers will be keenly observing the final subscription numbers and subsequent market performance
You must be logged in to post a comment.